Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

173 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer.
Herberts C, Murtha AJ, Fu S, Wang G, Schönlau E, Xue H, Lin D, Gleave A, Yip S, Angeles A, Hotte S, Tran B, North S, Taavitsainen S, Beja K, Vandekerkhove G, Ritch E, Warner E, Saad F, Iqbal N, Nykter M, Gleave ME, Wang Y, Annala M, Chi KN, Wyatt AW. Herberts C, et al. Among authors: nykter m. Eur Urol. 2020 Dec;78(6):834-844. doi: 10.1016/j.eururo.2020.04.058. Epub 2020 May 22. Eur Urol. 2020. PMID: 32451180
Fusion genes and their discovery using high throughput sequencing.
Annala MJ, Parker BC, Zhang W, Nykter M. Annala MJ, et al. Among authors: nykter m. Cancer Lett. 2013 Nov 1;340(2):192-200. doi: 10.1016/j.canlet.2013.01.011. Epub 2013 Jan 29. Cancer Lett. 2013. PMID: 23376639 Free PMC article. Review.
DOT1L-HES6 fusion drives androgen independent growth in prostate cancer.
Annala M, Kivinummi K, Leinonen K, Tuominen J, Zhang W, Visakorpi T, Nykter M. Annala M, et al. Among authors: nykter m. EMBO Mol Med. 2014 Sep;6(9):1121-3. doi: 10.15252/emmm.201404210. EMBO Mol Med. 2014. PMID: 25006183 Free PMC article. No abstract available.
Recurrent SKIL-activating rearrangements in ETS-negative prostate cancer.
Annala M, Kivinummi K, Tuominen J, Karakurt S, Granberg K, Latonen L, Ylipää A, Sjöblom L, Ruusuvuori P, Saramäki O, Kaukoniemi KM, Yli-Harja O, Vessella RL, Tammela TL, Zhang W, Visakorpi T, Nykter M. Annala M, et al. Among authors: nykter m. Oncotarget. 2015 Mar 20;6(8):6235-50. doi: 10.18632/oncotarget.3359. Oncotarget. 2015. PMID: 25749039 Free PMC article.
The evolutionary history of lethal metastatic prostate cancer.
Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JMC, Papaemmanuil E, Brewer DS, Kallio HML, Högnäs G, Annala M, Kivinummi K, Goody V, Latimer C, O'Meara S, Dawson KJ, Isaacs W, Emmert-Buck MR, Nykter M, Foster C, Kote-Jarai Z, Easton D, Whitaker HC; ICGC Prostate Group; Neal DE, Cooper CS, Eeles RA, Visakorpi T, Campbell PJ, McDermott U, Wedge DC, Bova GS. Gundem G, et al. Among authors: nykter m. Nature. 2015 Apr 16;520(7547):353-357. doi: 10.1038/nature14347. Epub 2015 Apr 1. Nature. 2015. PMID: 25830880 Free PMC article.
Epigenetically altered miR-193b targets cyclin D1 in prostate cancer.
Kaukoniemi KM, Rauhala HE, Scaravilli M, Latonen L, Annala M, Vessella RL, Nykter M, Tammela TL, Visakorpi T. Kaukoniemi KM, et al. Among authors: nykter m. Cancer Med. 2015 Sep;4(9):1417-25. doi: 10.1002/cam4.486. Epub 2015 Jul 1. Cancer Med. 2015. PMID: 26129688 Free PMC article.
173 results